PEGBIO CO-B (02565) completed the issuance of a total of 5.136 million shares for subscription.
Peg Bio-pharma-B (02565) announced that all conditions of the placement agreement have been met, and the placement was completed on December 22, 2025. In accordance with the terms and conditions of the placement agreement, the joint placing agents have placed a total of 5,136,000 placement shares with no less than 6 placees at a price of HK$58.41 per share, representing approximately 1.81% of the H Shares issued and expanded after the completion of the placement, and approximately 1.31% of the total number of shares.
PEGBIO CO-B(02565) announcement, all conditions of the subscription agreement have been met, and the subscription was completed on December 22, 2025. According to the terms and conditions of the subscription agreement, the joint subscription agents have subscribed a total of 5.136 million shares to no fewer than 6 subscribers at a price of HK$58.41 per share, representing approximately 1.81% of the H shares outstanding after the completion of the subscription, and approximately 1.31% of the total number of shares.
Related Articles
US Stock Market Move | The concept of encrypted cryptocurrency stocks continues to rise, with Hut 8 (HUT.US) rising nearly 12%.
Deutsche Bank initiates coverage on Uxin Ltd. Sponsored ADR (UXIN.US) for the first time: assign a target price of $4.5 USD, optimistic about its "superstore" model.
China Railway Construction Corporation (01186) plans to issue no more than 4.5 billion yuan of renewable corporate bonds.
US Stock Market Move | The concept of encrypted cryptocurrency stocks continues to rise, with Hut 8 (HUT.US) rising nearly 12%.
Deutsche Bank initiates coverage on Uxin Ltd. Sponsored ADR (UXIN.US) for the first time: assign a target price of $4.5 USD, optimistic about its "superstore" model.
China Railway Construction Corporation (01186) plans to issue no more than 4.5 billion yuan of renewable corporate bonds.
